These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35855557)

  • 21. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.
    Cavender MA; Scirica BM; Bonaca MP; Angiolillo DJ; Dalby AJ; Dellborg M; Morais J; Murphy SA; Ophuis TO; Tendera M; Braunwald E; Morrow DA
    Circulation; 2015 Mar; 131(12):1047-53. PubMed ID: 25681464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease.
    Kohli P; Steg PG; Cannon CP; Smith SC; Eagle KA; Ohman EM; Alberts MJ; Hoffman E; Guo J; Simon T; Sorbets E; Goto S; Bhatt DL;
    Am J Med; 2014 Jan; 127(1):53-60.e1. PubMed ID: 24280110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship of diabetes, heart failure, and N-terminal pro-B-type natriuretic peptide with cardiovascular outcomes in patients with atrial fibrillation.
    Hofer F; Pailer U; Sulzgruber P; Gerges C; Winter MP; Giugliano RP; Gottsauner-Wolf M; Hülsmann M; Kazem N; Koller L; Schönbauer R; Niessner A; Hengstenberg C; Zelniker TA
    ESC Heart Fail; 2022 Aug; 9(4):2367-2377. PubMed ID: 35593128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis.
    Cavallari I; Morrow DA; Creager MA; Olin J; Bhatt DL; Steg PG; Storey RF; Cohen M; Scirica BS; Piazza G; Goodrich EL; Braunwald E; Sabatine MS; Bonaca MP
    Circulation; 2018 Feb; 137(7):684-692. PubMed ID: 29084737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
    Verma S; Sharma A; Zinman B; Ofstad AP; Fitchett D; Brueckmann M; Wanner C; Zwiener I; George JT; Inzucchi SE; Butler J; Mazer CD
    Diabetes Obes Metab; 2020 Jul; 22(7):1141-1150. PubMed ID: 32227432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Singh AK; Singh R
    Diabetes Metab Syndr; 2021; 15(1):351-359. PubMed ID: 33503584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trial.
    Bonaca MP; Scirica BM; Braunwald E; Wiviott SD; O'Donoghue ML; Murphy SA; Morrow DA
    J Am Coll Cardiol; 2014 Dec; 64(22):2309-17. PubMed ID: 25465416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure.
    Everett BM; Cornel JH; Lainscak M; Anker SD; Abbate A; Thuren T; Libby P; Glynn RJ; Ridker PM
    Circulation; 2019 Mar; 139(10):1289-1299. PubMed ID: 30586730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
    Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
    Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
    Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
    Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
    JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX; Liang S; Gao L; Liu H
    PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.
    Bonaca MP; Wiviott SD; Zelniker TA; Mosenzon O; Bhatt DL; Leiter LA; McGuire DK; Goodrich EL; De Mendonca Furtado RH; Wilding JPH; Cahn A; Gause-Nilsson IAM; Johanson P; Fredriksson M; Johansson PA; Langkilde AM; Raz I; Sabatine MS
    Circulation; 2020 Aug; 142(8):734-747. PubMed ID: 32795086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
    Furtado RHM; Bonaca MP; Raz I; Zelniker TA; Mosenzon O; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Nicolau JC; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2516-2527. PubMed ID: 30882239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of adverse cardiovascular events in type 2 diabetes mellitus patients after initiation of glucose-lowering agents: A population-based community study from the Shizuoka Kokuho database.
    Kohsaka S; Kumamaru H; Nishimura S; Shoji S; Nakatani E; Ichihara N; Yamamoto H; Miyachi Y; Miyata H
    J Diabetes Investig; 2021 Aug; 12(8):1452-1461. PubMed ID: 33345452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.
    Nauck MA; McGuire DK; Pieper KS; Lokhnygina Y; Strandberg TE; Riefflin A; Delibasi T; Peterson ED; White HD; Scott R; Holman RR
    Cardiovasc Diabetol; 2019 Sep; 18(1):116. PubMed ID: 31481069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sulphonylureas monotherapy and risk of hospitalization for heart failure in patients with type 2 diabetes mellitus: A population-based cohort study in China.
    Xu Y; Wang T; Yang Z; Lin H; Shen P; Zhan S
    Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):635-643. PubMed ID: 32383226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial.
    Oyama K; Raz I; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Park KS; Goudev A; Diaz R; Špinar J; Gause-Nilsson IAM; Mosenzon O; Sabatine MS; Wiviott SD
    Eur Heart J; 2022 Aug; 43(31):2958-2967. PubMed ID: 34427295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease.
    Toth PP; Schwartz GG; Nicholls SJ; Khan A; Szarek M; Ginsberg HN; Johansson JO; Kalantar-Zadeh K; Kulikowski E; Lebioda K; Wong NCW; Sweeney M; Ray KK;
    Am J Prev Cardiol; 2022 Sep; 11():100372. PubMed ID: 36039183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.